** Shares of drug developer Cytokinetics CYTK.O fall 3.7% to $38.35 premarket
** Rival Bristol Myers Squibb BMY.N said late on Monday its drug, mavacamten, to treat a type of heart disease did not significantly improve functional capacity and symptoms in patients, failing to meet the main goals of a late-stage study
** CYTK is also developing an experimental heart drug, aficamten, to treat non-obstructive form of hypertrophic cardiomyopathy, an inherited condition characterized by thickening of heart muscles
** BofA says most of its prescribers see the two drugs as "more similar than not clinically"
** Brokerage suggests that there might be more discussions about the importance of this class of drugs for all patients, not just those with severe symptoms, due to ongoing uncertainties about the overall potential
** Up to last close, CYTK shares down 15.4%
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。